Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2017

01-05-2017 | Original Article

Thrombocytopaenia during methicillin-sensitive Staphylococcus aureus bacteraemia

Authors: E. Forsblom, I. Tielinen, E. Ruotsalainen, A. Järvinen

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2017

Login to get access

Abstract

The prognostic impact of thrombocytopaenia in Staphylococcus aureus bacteraemia (SAB) has previously been determined at bacteraemia onset only and relevant pre-bacteraemic thrombocytopaenia predisposing parameters have not been accounted for. We evaluated the prognostic impact of low thrombocyte count in SAB excluding pre-bacteraemic factors potentially causing thrombocytopaenia. This was a multicentre retrospective analysis of methicillin-sensitive SAB (MS-SAB) patients. Thrombocyte count was determined at blood culture collection and at days 3 and 7. Thrombocytopaenia was defined as a thrombocyte count less than 150 ×109/L. Patients with chronic alcoholism, liver diseases and haematologic malignancies were excluded. Altogether, 495 patients were identified. Thrombocytopaenia at blood culture and at day 3 associated to endocarditis (p < 0.05 and p < 0.01) and defervescence (p < 0.001 and p < 0.01). Mortality at 90 days was higher for patients with thrombocytopaenia at blood culture collection (26 vs. 16%, p < 0.05), at day 3 (32 vs. 13%, p < 0.01) and at day 7 (50 vs. 14%, p < 0.001). In receiver operating characteristic analyses, thrombocytopaenia predicted a poor outcome at blood culture collection (p < 0.05), at day 3 (p < 0.001) and at day 7 (p < 0.001). When accounting for all prognostic parameters, thrombocytopaenia at day 3 [hazard ratio (HR), 1.83; p = 0.05] demonstrated a trend towards poor outcome, whereas thrombocytopaenia at day 7 (HR, 3.64; p < 0.001) associated to poor outcome. Thrombocytopaenia at blood culture collection was not a prognostic parameter when all prognostic factors were taken into account. However, thrombocytopaenia at day 3 indicated a poor outcome and thrombocytopaenia at day 7 was a significant independent negative prognostic marker that has not been previously reported in SAB.
Literature
1.
go back to reference Rieg S, Peyerl-Hoffmann G, de With K et al (2009) Mortality of S. aureus bacteremia and infectious diseases specialist consultation—a study of 521 patients in Germany. J Infect 59:232–239CrossRefPubMed Rieg S, Peyerl-Hoffmann G, de With K et al (2009) Mortality of S. aureus bacteremia and infectious diseases specialist consultation—a study of 521 patients in Germany. J Infect 59:232–239CrossRefPubMed
2.
go back to reference Forsblom E, Ruotsalainen E, Mölkänen T, Ollgren J, Lyytikäinen O, Järvinen A (2011) Predisposing factors, disease progression and outcome in 430 prospectively followed patients of healthcare- and community-associated Staphylococcus aureus bacteraemia. J Hosp Infect 78:102–107CrossRefPubMed Forsblom E, Ruotsalainen E, Mölkänen T, Ollgren J, Lyytikäinen O, Järvinen A (2011) Predisposing factors, disease progression and outcome in 430 prospectively followed patients of healthcare- and community-associated Staphylococcus aureus bacteraemia. J Hosp Infect 78:102–107CrossRefPubMed
3.
go back to reference Thwaites GE, Edgeworth JD, Gkrania-Klotsas E et al (2011) Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis 11:208–222CrossRefPubMed Thwaites GE, Edgeworth JD, Gkrania-Klotsas E et al (2011) Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis 11:208–222CrossRefPubMed
4.
go back to reference Fowler VG Jr, Olsen MK, Corey GR et al (2003) Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 163:2066–2072CrossRefPubMed Fowler VG Jr, Olsen MK, Corey GR et al (2003) Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 163:2066–2072CrossRefPubMed
5.
go back to reference Chang FY, Peacock JE Jr, Musher DM et al (2003) Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82:333–339CrossRef Chang FY, Peacock JE Jr, Musher DM et al (2003) Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82:333–339CrossRef
6.
go back to reference Lodise TP, McKinnon PS, Swiderski L, Rybak MJ (2003) Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 36:1418–1423CrossRefPubMed Lodise TP, McKinnon PS, Swiderski L, Rybak MJ (2003) Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 36:1418–1423CrossRefPubMed
7.
go back to reference Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53–59CrossRefPubMed Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53–59CrossRefPubMed
8.
go back to reference Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, Beach ML (1999) Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn Microbiol Infect Dis 33:283–297CrossRefPubMed Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, Beach ML (1999) Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn Microbiol Infect Dis 33:283–297CrossRefPubMed
9.
go back to reference Siegman-Igra Y, Reich P, Orni-Wasserlauf R, Schwartz D, Giladi M (2005) The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis 37:572–578CrossRefPubMed Siegman-Igra Y, Reich P, Orni-Wasserlauf R, Schwartz D, Giladi M (2005) The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis 37:572–578CrossRefPubMed
10.
go back to reference Kim SH, Kim KH, Kim HB et al (2008) Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 52:192–197CrossRefPubMed Kim SH, Kim KH, Kim HB et al (2008) Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 52:192–197CrossRefPubMed
11.
go back to reference Forsblom E, Ruotsalainen E, Ollgren J, Järvinen A (2013) Telephone consultation cannot replace bedside infectious disease consultation in the management of Staphylococcus aureus bacteremia. Clin Infect Dis 56:527–535CrossRefPubMed Forsblom E, Ruotsalainen E, Ollgren J, Järvinen A (2013) Telephone consultation cannot replace bedside infectious disease consultation in the management of Staphylococcus aureus bacteremia. Clin Infect Dis 56:527–535CrossRefPubMed
12.
go back to reference Ringberg H, Thorén A, Lilja B (2000) Metastatic complications of Staphylococcus aureus septicemia. To seek is to find. Infection 28:132–136CrossRefPubMed Ringberg H, Thorén A, Lilja B (2000) Metastatic complications of Staphylococcus aureus septicemia. To seek is to find. Infection 28:132–136CrossRefPubMed
13.
go back to reference Pragman AA, Kuskowski MA, Abraham JM, Filice GA (2012) Infectious disease consultation for Staphylococcus aureus bacteremia improves patient management and outcomes. Infect Dis Clin Pract (Baltim Md) 20:261–267CrossRef Pragman AA, Kuskowski MA, Abraham JM, Filice GA (2012) Infectious disease consultation for Staphylococcus aureus bacteremia improves patient management and outcomes. Infect Dis Clin Pract (Baltim Md) 20:261–267CrossRef
15.
go back to reference Gafter-Gvili A, Mansur N, Bivas A et al (2011) Thrombocytopenia in Staphylococcus aureus bacteremia: risk factors and prognostic importance. Mayo Clin Proc 86:389–396CrossRefPubMedPubMedCentral Gafter-Gvili A, Mansur N, Bivas A et al (2011) Thrombocytopenia in Staphylococcus aureus bacteremia: risk factors and prognostic importance. Mayo Clin Proc 86:389–396CrossRefPubMedPubMedCentral
16.
go back to reference Spika JS, Peterson PK, Wilkinson BJ et al (1982) Role of peptidoglycan from Staphylococcus aureus in leukopenia, thrombocytopenia, and complement activation associated with bacteremia. J Infect Dis 146:227–234CrossRefPubMed Spika JS, Peterson PK, Wilkinson BJ et al (1982) Role of peptidoglycan from Staphylococcus aureus in leukopenia, thrombocytopenia, and complement activation associated with bacteremia. J Infect Dis 146:227–234CrossRefPubMed
17.
go back to reference Fitzgerald JR, Foster TJ, Cox D (2006) The interaction of bacterial pathogens with platelets. Nat Rev Microbiol 4:445–457CrossRefPubMed Fitzgerald JR, Foster TJ, Cox D (2006) The interaction of bacterial pathogens with platelets. Nat Rev Microbiol 4:445–457CrossRefPubMed
18.
go back to reference de Haas CJ, Weeterings C, Vughs MM, de Groot PG, Van Strijp JA, Lisman T (2009) Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibalpha and alpha IIb beta 3. J Thromb Haemost 7:1867–1874CrossRefPubMed de Haas CJ, Weeterings C, Vughs MM, de Groot PG, Van Strijp JA, Lisman T (2009) Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibalpha and alpha IIb beta 3. J Thromb Haemost 7:1867–1874CrossRefPubMed
19.
go back to reference Kerrigan SW, Clarke N, Loughman A, Meade G, Foster TJ, Cox D (2008) Molecular basis for Staphylococcus aureus-mediated platelet aggregate formation under arterial shear in vitro. Arterioscler Thromb Vasc Biol 28:335–340CrossRefPubMed Kerrigan SW, Clarke N, Loughman A, Meade G, Foster TJ, Cox D (2008) Molecular basis for Staphylococcus aureus-mediated platelet aggregate formation under arterial shear in vitro. Arterioscler Thromb Vasc Biol 28:335–340CrossRefPubMed
20.
go back to reference George NP, Konstantopoulos K, Ross JM (2007) Differential kinetics and molecular recognition mechanisms involved in early versus late growth phase Staphylococcus aureus cell binding to platelet layers under physiological shear conditions. J Infect Dis 196:639–646CrossRefPubMed George NP, Konstantopoulos K, Ross JM (2007) Differential kinetics and molecular recognition mechanisms involved in early versus late growth phase Staphylococcus aureus cell binding to platelet layers under physiological shear conditions. J Infect Dis 196:639–646CrossRefPubMed
21.
go back to reference Buyukasýk NS, Ileri M, Alper A et al (2004) Increased blood coagulation and platelet activation in patients with infective endocarditis and embolic events. Clin Cardiol 27:154–158CrossRefPubMed Buyukasýk NS, Ileri M, Alper A et al (2004) Increased blood coagulation and platelet activation in patients with infective endocarditis and embolic events. Clin Cardiol 27:154–158CrossRefPubMed
22.
go back to reference Hart RG, Foster JW, Luther MF, Kanter MC (1990) Stroke in infective endocarditis. Stroke 21:695–700CrossRefPubMed Hart RG, Foster JW, Luther MF, Kanter MC (1990) Stroke in infective endocarditis. Stroke 21:695–700CrossRefPubMed
23.
go back to reference Wang JL, Chen SY, Wang JT et al (2008) Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Clin Infect Dis 46:799–806CrossRefPubMed Wang JL, Chen SY, Wang JT et al (2008) Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Clin Infect Dis 46:799–806CrossRefPubMed
24.
go back to reference Wang JT, Wu HS, Weng CM, Hsu LY, Wang FD (2013) Prognosis of patients with methicillin-resistant Staphylococcus aureus bloodstream infection treated with teicoplanin: a retrospective cohort study investigating effect of teicoplanin minimum inhibitory concentrations. BMC Infect Dis 13:182CrossRefPubMedPubMedCentral Wang JT, Wu HS, Weng CM, Hsu LY, Wang FD (2013) Prognosis of patients with methicillin-resistant Staphylococcus aureus bloodstream infection treated with teicoplanin: a retrospective cohort study investigating effect of teicoplanin minimum inhibitory concentrations. BMC Infect Dis 13:182CrossRefPubMedPubMedCentral
25.
go back to reference Wang JT, Hsu LY, Lauderdale TL, Fan WC, Wang FD (2015) Comparison of outcomes among adult patients with Nosocomial bacteremia caused by methicillin-susceptible and methicillin-resistant Staphylococcus aureus: a retrospective cohort study. PLoS One 10(12):e0144710CrossRefPubMedPubMedCentral Wang JT, Hsu LY, Lauderdale TL, Fan WC, Wang FD (2015) Comparison of outcomes among adult patients with Nosocomial bacteremia caused by methicillin-susceptible and methicillin-resistant Staphylococcus aureus: a retrospective cohort study. PLoS One 10(12):e0144710CrossRefPubMedPubMedCentral
26.
go back to reference Paul M, Kariv G, Goldberg E et al (2010) Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 65:2658–2665CrossRefPubMed Paul M, Kariv G, Goldberg E et al (2010) Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 65:2658–2665CrossRefPubMed
27.
go back to reference Paul M, Zemer-Wassercug N, Talker O et al (2011) Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect 17:1581–1586CrossRefPubMed Paul M, Zemer-Wassercug N, Talker O et al (2011) Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect 17:1581–1586CrossRefPubMed
28.
go back to reference Bishara J, Goldberg E, Leibovici L et al (2012) Healthcare-associated vs. hospital-acquired Staphylococcus aureus bacteremia. Int J Infect Dis 16:e457–e463CrossRefPubMed Bishara J, Goldberg E, Leibovici L et al (2012) Healthcare-associated vs. hospital-acquired Staphylococcus aureus bacteremia. Int J Infect Dis 16:e457–e463CrossRefPubMed
29.
go back to reference Ruotsalainen E, Järvinen A, Koivula I et al (2006) Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. J Intern Med 259:179–190CrossRefPubMed Ruotsalainen E, Järvinen A, Koivula I et al (2006) Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. J Intern Med 259:179–190CrossRefPubMed
30.
go back to reference Forsblom E, Ruotsalainen E, Järvinen A (2015) Improved outcome with early rifampicin combination treatment in methicillin-sensitive Staphylococcus aureus bacteraemia with a deep infection focus—a retrospective cohort study. PLoS One 10:e0122824CrossRefPubMedPubMedCentral Forsblom E, Ruotsalainen E, Järvinen A (2015) Improved outcome with early rifampicin combination treatment in methicillin-sensitive Staphylococcus aureus bacteraemia with a deep infection focus—a retrospective cohort study. PLoS One 10:e0122824CrossRefPubMedPubMedCentral
31.
go back to reference McCabe WR, Jackson GG (1962) Gram-negative bacteremia: I. Etiology and ecology. Arch Intern Med 110:847–855CrossRef McCabe WR, Jackson GG (1962) Gram-negative bacteremia: I. Etiology and ecology. Arch Intern Med 110:847–855CrossRef
32.
go back to reference Levy MM, Fink MP, Marshall JC et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250–1256CrossRefPubMed Levy MM, Fink MP, Marshall JC et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250–1256CrossRefPubMed
33.
go back to reference Li JS, Sexton DJ, Mick N et al (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30:633–638CrossRefPubMed Li JS, Sexton DJ, Mick N et al (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30:633–638CrossRefPubMed
34.
go back to reference Levi M, Toh CH, Thachil J, Watson HG (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 145:24–33CrossRefPubMed Levi M, Toh CH, Thachil J, Watson HG (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 145:24–33CrossRefPubMed
35.
go back to reference Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ (1995) Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23:1638–1652CrossRefPubMed Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ (1995) Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23:1638–1652CrossRefPubMed
36.
go back to reference Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758CrossRefPubMed Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758CrossRefPubMed
37.
38.
go back to reference Akca S, Haji-Michael P, de Mendonça A, Suter P, Levi M, Vincent JL (2002) Time course of platelet counts in critically ill patients. Crit Care Med 30:753–756CrossRefPubMed Akca S, Haji-Michael P, de Mendonça A, Suter P, Levi M, Vincent JL (2002) Time course of platelet counts in critically ill patients. Crit Care Med 30:753–756CrossRefPubMed
39.
go back to reference Sy RW, Chawantanpipat C, Richmond DR, Kritharides L (2008) Thrombocytopenia and mortality in infective endocarditis. J Am Coll Cardiol 51:1824–1825CrossRefPubMed Sy RW, Chawantanpipat C, Richmond DR, Kritharides L (2008) Thrombocytopenia and mortality in infective endocarditis. J Am Coll Cardiol 51:1824–1825CrossRefPubMed
40.
go back to reference Nijsten MW, ten Duis HJ, Zijlstra JG et al (2000) Blunted rise in platelet count in critically ill patients is associated with worse outcome. Crit Care Med 28:3843–3846CrossRefPubMed Nijsten MW, ten Duis HJ, Zijlstra JG et al (2000) Blunted rise in platelet count in critically ill patients is associated with worse outcome. Crit Care Med 28:3843–3846CrossRefPubMed
Metadata
Title
Thrombocytopaenia during methicillin-sensitive Staphylococcus aureus bacteraemia
Authors
E. Forsblom
I. Tielinen
E. Ruotsalainen
A. Järvinen
Publication date
01-05-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2877-4

Other articles of this Issue 5/2017

European Journal of Clinical Microbiology & Infectious Diseases 5/2017 Go to the issue

Letter to the Editor

Author’s reply

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.